Incretin and metabolic receptor research: retatrutide, tirzepatide.
All research areas 3 articles
Tirzepatide is a single 39-residue peptide that activates two incretin receptors, GIP and GLP-1. Its phase 3 trials in type 2 diabetes and obesity are among the largest in the field. It is also an approved pharmaceutical, which sets it apart from most compounds in this library.
Retatrutide adds a third receptor to the incretin approach, activating GIP, GLP-1, and glucagon receptors at once. Two phase 2 trials in humans were published in 2023, in the New England Journal of Medicine and the Lancet.
Retatrutide is the first triple GIP, GLP-1, and glucagon receptor agonist to reach late-stage human trials. Two phase 2 trials in humans were published in 2023, one in the New England Journal of Medicine and one in the Lancet.
For research purposes only. Not for human or veterinary consumption. Not for use in diagnostic, therapeutic, or clinical procedures.
